News - Latest
53 news items
Changes to fees for human medicinal products and devices as of 1 January 2023
With effect from 1 January 2023, the Medicines Evaluation Board (MEB) will be increasing the fees for authorisation applications, ...
Registering the continued use of antimycotics or antiprotozoal veterinary medicinal products exclusively intended for specific companion animals
Prior to the introduction of the Veterinary Medicinal Products Regulation, antimycotics (antifungal agents) and antiprotozoal ...
Veterinary Medicinal Products Unit Fees for 2023 in revised Veterinary Medicinal Products Regulation 2022
With effect from 1 January 2023, the Medicines Evaluation Board (MEB) will be increasing the fees. The fees of the Veterinary ...
New issue of Regulatory Science Magazine
A significant portion of the potential anticancer medicines that reach the clinical phase do not make it to registration. This is ...
Amended procedure for sending, communicating and publishing letters and decisions
The Veterinary Medicinal Products Unit has set in motion a number of changes to the sending, communicating and publishing letters ...
Form for specifying an e-mail address for receipt of digital decisions
As from 1 October, the Veterinary Medicinal Products Unit will no longer send marketing authorisations in hard copy. We ask all ...
Changes to application forms and invitation to participate in the Veterinary Medicines Information Database survey
The new Veterinary Medicinal Products Regulation came into force on 28 January 2022. Among many other consequences, this ...
All MEB correspondence on human medicines will in future be sent by email
From 1 July 2022, all correspondence from the Medicines Evaluation Board on human medicines will be sent by email. Correspondence ...
MEB Annual Report 2021: Looking ahead
The coronavirus had a big impact on the year 2021, just like it did in 2020. It made 2021 very special year once again. In the ...
Amended policy on national implementation of additional risk minimisation measures
The Medicines Evaluation Board (MEB) has amended its policy for the national implementation of additional risk minimisation ...